Cell-based reporter gene assay for therapy-induced neutralizing antibodies to interferon-beta in multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 33, Issue 2, 2013, Pages 52-57

  Martins, Thomas B ^a   Rose, John W ^b   Gardiner, Gareth L ^a   Kusukawa, Noriko ^a   Husebye, Dee ^b   Hill, Harry R ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; DRUG ANTIBODY; INTERFERON BETA SERINE; LUCIFERASE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOPATHOGENIC EFFECT; DISEASE COURSE; DISEASE DURATION; ELECTROENCEPHALOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FEMALE; FUNCTIONAL ASSESSMENT; GENETIC PROCEDURES; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REPORTER GENE; REPORTER GENE ASSAY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VIRUS CULTURE; VIRUS INHIBITION;

ANTIBODIES, NEUTRALIZING; CASE-CONTROL STUDIES; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; GENES, REPORTER; HUMANS; IMMUNOASSAY; INTERFERON-BETA; LUCIFERASES; MULTIPLE SCLEROSIS; SENSITIVITY AND SPECIFICITY; TRANSFECTION;

EID: 84873663203     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0027     Document Type: Article

References (31)

1. Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P. 2004. Immunogenicity of interferon beta: differences among products. J Neurol 251(Suppl. 2):II15-II24.
2. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R. 2000. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48:95-100. (Pubitemid 30608666)
3. Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capo-bianco M, Milano E, Melis F, Giordana MT. 2002. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148-153.
4. Brettschneider J, Jaskowski TD, Tumani H, Abdul S, Husebye D, Seraj H, Hill HR, Fire E, Spector L, Yarden J, Dotan N, Rose JW. 2009. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 217:95-101.
5. Farrell R, Kapoor R, Leary S, Rudge P, Thompson A, Miller D, Giovannoni G. 2008. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult Scler 14:212-218. (Pubitemid 351639630)
6. Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G. 2011. Incorporation of an interferon-beta neutralizing antibody assay into routine clinical practice. Mult Scler 17:1333-1340.
7. Fernandez O, Mayorga C, Luque G, Guerrero M, Guerrero R, Leyva L, Leon A, Blanca M. 2001. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients. J Neurol 248: 383-388. (Pubitemid 32477329)
8. Grossberg SE, Kawade Y, Kohase M, Klein JP. 2001a. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 21:743-755. (Pubitemid 32955704)
9. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. 2001b. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 21:729-742. (Pubitemid 32955703)
10. Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. 2007. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J Neurol 254:827-837. (Pubitemid 47222316)
11. Kawade Y. 1985. Neutralization of activity of effector protein by monoclonal antibody: formulation of antibody dose-dependence of neutralization for an equilibrium system of antibody, effector, and its cellular receptor. Immunology 56:497-504. (Pubitemid 15245004)
12. Kawade Y, Watanabe Y. 1984. Neutralization of interferon by antibody: appraisals of methods of determining and expressing the neutralization titer. J Interferon Res 4:571-584. (Pubitemid 14023313)
13. Lallemand C, Meritet JF, Erickson R, Grossberg SE, Roullet E, Lyon-Caen O, Lebon P, Tovey MG. 2008. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res 28:393-404. (Pubitemid 351929939)
14. Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J. 2008. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods 336:113-118.
15. Lublin FD, Reingold SC. 1996. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-911.
16. Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A. 2004. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 62:2031-2037. (Pubitemid 38738217)
17. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127.
18. McKay F, Schibeci S, Heard R, Stewart G, Booth D. 2006. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. J Immunol Methods 310:20-29. (Pubitemid 43375972)
19. Pachner AR. 2003. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 61:1444-1446. (Pubitemid 37463391)
20. Pachner AR, Dail D, Pak E, Narayan K. 2005. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 166:180-188. (Pubitemid 41078773)
21. Pachner AR, Narayan K, Pak E. 2006. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology 66:444-446. (Pubitemid 43739958)
22. Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT investigators. 2009. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology 73:1493-1500.
23. Perini P, Calabrese M, Biasi G, Gallo P. 2004. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 251:305-309. (Pubitemid 38387148)
24. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. 2011. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292-302.
25. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. 2005. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58:840-846. (Pubitemid 41746873)
26. Prince HE, Lape-Nixon M, Audette C, Van Horn K. 2007. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera. J Neu-roimmunol 190:165-169. (Pubitemid 47625613)
27. Rose JW, Carlson NG. 2011. Clinical biomarkers in multiple sclerosis. Expert Opin Med Diagn 5:213-226.
28. Ross C, Clemmesen KM, Sorensen PS, Koch-Henriksen N, Bendtzen K. 2006. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult Scler 12:39-46. (Pubitemid 43169236)
29. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K. 2000. Immuno-genicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish multiple sclerosis study group. Ann Neurol 48:706-712.
30. Sorensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C. 2005a. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12:817-827. (Pubitemid 41597593)
31. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. 2005b. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65:33-39. (Pubitemid 40967773)